The Rationale for the Phase I TRANSCEND NHL 001 Trial

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the rationale for phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory large B-cell lymphoma, which were presented at the 2019 American Society of Hematology Annual Meeting.

TRANSCEND-NHL 001 was launched to serve an unmet medical need for new treatment options in this patient population. Conventional therapies have a low single-agent response rate, no chance of cure, and median overall survival of 6 month or less in these patient. The hope was that liso-cel would improve outcomes and quality of life in these patients, says Abramson.

For more about the TRANCEND-NHL 001 trialhttps://www.targetedonc.com/news/fda-grant-priority-review-to-lisocel-in-relapsedrefractory-large-bcell-lymphoma

Related Videos
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Related Content